View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2013	Nov. 01, 2013
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Entity Registrant Name	CHIMERIX INC
Entity Central Index Key	0001117480
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		26,420,393

Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 115,891	$ 19,906
Short-term investments, available-for-sale	1,004	9,849
Accounts receivable	190	783
Prepaid and other current assets	2,683	983
Deferred financing costs, current portion	20	33
Total current assets	119,788	31,554
Property and equipment, net of accumulated depreciation	335	407
Deposits	20	22
Deferred financing costs, less current portion	15	48
Total assets	120,158	32,031
Current liabilities:
Accounts payable	1,770	1,964
Accrued liabilities	1,601	906
Loan payable, current portion	5,597	4,753
Total current liabilities	8,968	7,623
Other long-term liabilities	345	337
Loan payable, less current portion	5,715	9,867
Redeemable convertible preferred stock warrant liability		7,512
Total liabilities	15,028	25,339
Redeemable convertible preferred stock		107,723
Stockholders' equity (deficit):
Common stock, $0.001 par value, 200,000,000 and 89,700,000 shares authorized at September 30, 2013 and December 31, 2012, respectively; 25,974,809 and 1,533,996 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively	26	3
Additional paid-in capital	259,661
Accumulated other comprehensive loss		(2)
Accumulated deficit	(154,557)	(101,032)
Total stockholders' equity (deficit)	105,130	(101,031)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$ 120,158	$ 32,031

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2013	Dec. 31, 2012
Balance Sheets [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	89,700,000
Common stock, shares issued	25,974,809	1,533,996
Common stock, shares outstanding	25,974,809	1,533,996

Statements Of Operations And Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Contract revenue	$ 912	$ 3,411	$ 3,491	$ 12,694
Collaboration and licensing revenue		17,445		17,445
Total revenues	912	20,856	3,491	30,139
Operating expenses:
Research and development	5,319	7,748	18,379	23,823
General and administrative	2,029	1,836	5,753	4,956
(Loss) income from operations	(6,436)	11,272	(20,641)	1,360
Other expense:
Interest expense, net	(270)	(130)	(1,041)	(367)
Fair value adjustments to warrant liability			(6,590)	(1,073)
Net (loss) income	(6,706)	11,142	(28,272)	(80)
Other comprehensive gain (loss):
Unrealized gain (loss) on securities available-for-sale	1	(3)	3	4
Comprehensive (loss) income	$ (6,705)	$ 11,139	$ (28,269)	$ (76)
Per share information:
Net (loss) income per common share, basic	$ (0.26)	$ 6.70	$ (3.69)	$ (1.82)
Weighted-average shares outstanding, basic	25,866,109	1,529,442	16,911,592	1,524,489
Net (loss) income per common share, diluted	$ (0.26)	$ 0.11	$ (3.69)	$ (1.82)
Weighted-average shares outstanding, diluted	25,866,109	52,933,956	16,911,592	1,524,489

Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
Statements Of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2013	Sep. 30, 2012
Operating activities:
Net (loss) income	$ (28,272)	$ (80)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	197	210
Non-cash interest expense	46	175
Amortization/accretion of premium/discount on investments	416	29
Share-based compensation costs	2,853	1,133
Fair value measurement of redeemable convertible preferred stock warrant liability	6,590	1,073
Changes in operating assets and liabilities:
Accounts receivable	593	3,155
Prepaid expenses and other current assets and deposits	(1,698)	171
Accounts payable and accrued liabilities	501	(3,093)
Net cash (used) provided in operating activities	(18,774)	2,773
Investing Activities:
Purchase of property and equipment	(125)	(120)
Purchase of short-term investments	(1,852)
Sales of short-term investments	750
Maturities of short-term investments	9,758	5,893
Net cash provided by investing activities	8,531	5,773
Financing Activities:
Proceeds from exercise of stock options	582	8
Proceeds from exercise of warrants	1,537
Proceeds from loan payable		15,000
Proceeds from initial public offering, net of offering costs	107,634
Debt discount		(75)
Repayment of loan payable	(3,525)	(2,600)
Deferred financing costs		(24)
Net cash provided by financing activities	106,228	12,309
Increase in cash and cash equivalents	95,985	20,855
Cash and cash equivalents, beginning of period	19,906	13,607
Cash and cash equivalents, end of period	115,891	34,462
Supplemental cash flow information:
Interest payments	$ 862	$ 170

The Business and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2013

The Business and Summary of Significant Accounting Policies [Abstract]

The Business and Summary of Significant Accounting Policies

1. The Business and Summary of Significant Accounting Policies

Description of Business

Chimerix, Inc. (the Company) is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. The Company’s proprietary lipid technology has given rise to two clinical-stage compounds, brincidofovir (CMX001) and CMX157, which have demonstrated the potential for enhanced antiviral activity and safety in convenient, orally administered dosing regimens. The Company believes that brincidofovir has the potential to be the first broad-spectrum antiviral for the prevention and treatment of clinically significant infections and diseases caused by double-stranded DNA (dsDNA) viruses. Brincidofovir has shown broad-spectrum activity against dsDNA viruses, including herpesviruses, adenoviruses and polyomaviruses. Chimerix initiated the Phase 3 SUPPRESS trial in the third quarter of 2013 for the prevention of cytomegalovirus infection in hematopoietic cell transplant recipients. The Company recently completed a Phase 2 trial of brincidofovir as a preemptive therapy for adenovirus infection. Additionally, the Company is developing brincidofovir as a medical countermeasure against smallpox under a contract from the Biomedical Advanced Research and Development Authority (BARDA). The Company’s second clinical-stage compound, CMX157, is a Phase 1 product candidate for the treatment of HIV and was licensed to Merck, Sharp & Dohme Corp. (Merck) in 2012.

On March 25, 2013, the Company’s board of directors approved and implemented a 3.55-for-1 reverse stock split of the Company’s outstanding common stock. The reverse stock split resulted in an adjustment to the preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse stock split for all periods presented.

On April 10, 2013, the Company completed the initial public offering (IPO) of its common stock pursuant to a registration statement on Form S-1. In the IPO, the Company sold an aggregate of 7,320,000 shares of common stock under the registration statement at a public offering price of $14.00 per share. Net proceeds were approximately $93.3 million, after deducting underwriting discounts and commissions of $7.1 million and offering expenses of $2.1 million. Upon the completion of the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock and dividends accrued on Series F redeemable convertible preferred stock were converted into 15,556,091 shares of common stock and all outstanding warrants to purchase redeemable convertible preferred stock were converted into warrants to purchase 1,613,395 shares of common stock. On April 16, 2013, the underwriters exercised the full over-allotment option pursuant to which the Company sold an additional 1,098,000 shares at $14.00 per share. Net proceeds from the over-allotment shares were approximately $14.3 million after deducting underwriting discounts and commissions of $1.1 million.

On October 23, 2013, the Company completed an underwritten secondary public offering of 2,476,995 shares of common stock held by certain of the Company’s existing stockholders. The Company did not issue any shares of common stock and received no proceeds in connection with such offering. The principal purposes of the offering were to facilitate an orderly distribution of shares and to increase the Company’s public float.

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the Company’s financial statements requires estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Although these estimates are based on knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

The accompanying interim financial statements are unaudited. The unaudited interim financial statements have been prepared in accordance with GAAP on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the dates and periods presented herein. These financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s final prospectus dated April 10, 2013 filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the Securities and Exchange Commission on April 11, 2013. Interim operating results are not necessarily indicative of operating results for the full year.

Reclassifications

In certain instances, amounts previously reported in the Company’s 2012 financial statements have been reclassified to conform to the Company’s 2013 financial statement presentation. Such reclassifications had no effect on net loss or stockholders’ equity (deficit) as previously reported.

Cash and Cash Equivalents

The Company considers any highly liquid instrument with an original maturity of three months or less at acquisition to be a cash equivalent. Cash equivalents consist of money market accounts.

Investments

Investments consist primarily of corporate bonds and commercial paper. The Company invests in high-credit quality investments in accordance with its investment policy which minimizes the probability of loss.

Available-for-sale securities are carried at fair value as determined by quoted market prices, with the unrealized gains and losses, net of tax, reported as a separate component of stockholders deficit. Realized gains and losses are determined using the specific identification method and transactions are recorded on a settlement date basis in interest income or expense, net. Investments with original maturities beyond three months at the date of purchase and which mature on, or less than twelve months from, the balance sheet date are classified as long-term. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Any such declines in value judged to be other-than-temporary on available-for-sale securities are reported in interest income or expense, net. There were no such declines in value for the nine months ended September 30, 2013 and the year ended December 31, 2012.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents, short-term investments and accounts receivable. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. Accounts receivable represent amounts due from an agency of the federal government.

Accounts Receivable

Accounts receivable at September 30, 2013 and December 31, 2012 consisted of amounts billed and unbilled under the Company’s contract with BARDA. Receivables under the BARDA contract are recorded as qualifying research activities as conducted and invoices from the Company’s vendors are received. The Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded a charge to allowance for doubtful accounts as management believes all receivables are fully collectible.

Fair Value of Financial Instruments

The carrying amounts of certain financial instruments, including accounts receivable, notes receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of such instruments. The carrying amount of borrowings under loans payable approximates its fair value based on the determination that the stated rate on such loans payable is consistent with current interest rates for similar borrowing arrangements available to the Company.

For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates and are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, fair value measurements cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the calculated current or future fair values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.

The Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. These levels are:



Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.



Level 2 — Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and models for which all significant inputs are observable, either directly or indirectly.



Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The determination of where an asset or liability falls in the hierarchy requires significant judgment. The Company evaluates hierarchy disclosures and, based on various factors, it is possible that an asset or liability may be classified differently from period to period. However, the Company expects that changes in classification between levels will be rare.

The warrants issued for Series F redeemable convertible preferred stock included in the Company’s 2012 financial statements are categorized as Level 3 as there are significant unobservable inputs. The valuation of the warrants at December 31, 2012 reflected a two stage process. Using a contingent claims model in combination with the Company’s Series F financing, which occurred in February 2011, the fair value of total equity and all components of the Company’s capital structure, including the warrants, was determined as of the time of the financing event. Using this value as a starting point, a series of equity values and associated probabilities were calculated using simulation methodologies that incorporate both Monte Carlo and risk neutral frameworks. Based on assessments of expected returns and volatilities consistent with market practice, a distribution of equity values was produced which covered the range of values that an informed market participant might expect. These outcomes were organized into ranges and a probability calculated based on the percent of the total falling into each range. This process created a range of equity values. Using a contingent claims framework, each equity value was allocated to the various components of the capital structure including the warrants. Each warrant value was weighted by its respective probability to determine the final fair value of the warrants as of December 31, 2012. The key unobservable inputs used in the determination of the fair value were (i) volatility – 79%, (ii) range of implied fair value of the Series F redeemable convertible preferred stock – $2.19 to $2.85, (iii) time to liquidity – 8 months to 5 years, and (iv) range of probabilities of liquidity event outcomes – 2% to 31%. The warrants were valued again at April 10, 2013, just prior to the Company’s IPO, using a Black-Scholes valuation model. The key unobservable inputs used in determination of the fair value at that time were (i) volatility – 79%, (ii) fair value of the Series F redeemable convertible preferred stock – $3.94, (iii) expected life – 2.5 years, (iv) risk-free interest rate – 0.24%, and (v) dividend yield – 0%. As the warrants for Series F redeemable convertible preferred stock converted to warrants for common stock upon the IPO, no future valuations are necessary.

There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis.

Below is a table that presents information about certain assets and liabilities measured at fair value on a recurring basis:


			Fair Value Measurements at September 30, 2013
	September 30, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
	(in thousands)
Cash equivalents	$	113,816	$	113,816	$	—	$	—
Short-term investments		1,004		—		1,004		—


			Fair Value Measurements at December 31, 2012
	December 31, 2012		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
	(in thousands)
Cash equivalents	$	17,687	$	16,381	$	1,306	$	—
Short-term investments		9,849		—		9,849		—
Redeemable convertible preferred stock warrant liability		7,512		—		—		7,512

Below is a table that presents a reconciliation of the beginning and ending balances of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3):


	Fair Value Measurements (Level 3)
	(in thousands)
Redeemable Convertible Preferred Stock Warrant Liability
Balance at January 1, 2012	$	6,491
Issuance		174
Fair value increase recorded in other expense		847
Fair value at December 31, 2012		7,512
Fair value increase recorded in other expense		6,590
Reclassification of warrant liability to additional paid-in capital		(14,102	)
Fair value at September 30, 2013	$	—

Prepaid and Other Current Assets

Prepaid and other current assets consist of the following:


	September 30, 2013		December 31, 2012
	(in thousands)
Prepaid development expenses	$	2,241	$	486
Deferred public offering costs		—		273
Other prepaid and other current assets		442		224
	$	2,683	$	983

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Leasehold improvements are amortized over the shorter of the useful life of the asset or the term of the related lease. Maintenance and repairs are charged against expense as incurred.

Impairment of Long-Lived Assets

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than the carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. To date, no such write-downs have occurred.

Deferred Public Offering Costs

Deferred public offering costs totaling $0.3 million at December 31, 2012 are included in prepaid and other current assets. These costs represent legal and accounting costs related to the Company’s efforts to raise capital through an IPO. At the completion of the Company’s IPO in April 2013, these costs were reclassified to additional paid-in capital as a reduction of the IPO proceeds.

Deferred Rent

The Company recognizes rent expense on a straight-line basis over the non-cancelable term of its operating lease and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. The Company also records landlord-funded lease incentives, such as reimbursable leasehold improvements, as a deferred rent liability, which is amortized as a reduction of rent expense over the non-cancelable term of its operating lease.

Accrued Liabilities

Accrued liabilities consist of the following:


	September 30, 2013		December 31, 2012
	(in thousands)
Accrued compensation	$	565		$	560
Accrued development expenses		568			98
Other accrued liabilities		468			248
	$	1,601		$	906

Revenue Recognition

The Company’s revenues generally consist of (i) contract and grant revenues – revenues generated under federal contracts and other awarded grants, and (ii) collaboration and licensing revenues – revenues related to non-refundable upfront fees, royalties and milestone payments earned under license agreements. Revenues are recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.

For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. If the arrangement constitutes a single unit of accounting, the revenue recognition policy must be determined for the entire arrangement and the consideration received is recognized over the period of inception through the date the last deliverable within the single unit of accounting is expected to be delivered. Revisions to the estimated period of recognition are reflected in revenue prospectively.

Non-refundable upfront fees are recorded as deferred revenue and recognized into revenue as license fees from collaborations on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.

Research and Development

Major components of research and development costs include cash compensation, stock based compensation, pre-clinical studies, clinical trial and related clinical manufacturing, drug development, materials and supplies, legal, regulatory compliance, and fees paid to consultants and other entities that conduct certain research and development activities of the Company’s behalf. Research and development costs, including upfront fees and milestones paid to contract research organizations, are expensed as goods as received or services rendered. Costs incurred in connection with clinical trial activities for which the underlying nature of the activities themselves do not directly relate to active research and development, such as costs incurred for market research and focus groups linked to clinical strategy as well as costs to build the Company’s brand, are not included in research and development costs but are reflected as general and administrative costs.

Interest Expense, Net

Interest expense, net includes interest earned on short-term investments, interest incurred on loans payable, the amortization of deferred financing costs related to fees paid to attorneys and other non-lender entities in order to acquire debt, and the amortization of debt discount related to fees paid to the lender in order to acquire debt.

Income Taxes

Deferred tax assets and liabilities are determined based on differences between the financial and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when the Company determines that it is more likely than not that some portion of a deferred tax asset will not be realized. The Company has incurred operating losses from April 7, 2000 (inception) through September 30, 2013, and therefore has not recorded any current provision for income taxes.

Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions.

Share-Based Compensation

The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values. The fair value of share-based awards is estimated on the grant date using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods.

The Company also accounts for equity instruments issued to non-employees using a fair value approach. The Company values equity instruments, stock options and warrants granted to lenders and consultants using the Black-Scholes valuation model. The measurement of non-employee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received.

Basic and Dilutive Net (Loss) Income Per Share of Common Stock

Basic net (loss) income per share of common stock is computed by dividing net (loss) income by the weighted-average number of shares of common stock outstanding during the period, excluding the dilutive effects of converting redeemable convertible preferred stock, warrants to purchase redeemable convertible preferred stock and common stock, restricted stock and options. All undistributed earnings are allocated first to the preferred shareholders based on their contractual rights to dividends. This right is calculated on a pro rated basis for the portion of the period the preferred shares were outstanding. Any remaining undistributed earnings are allocated between preferred and common shares on a weighted average basis. Prior to the IPO, the Company had common stock and redeemable convertible preferred stock outstanding.

Therefore, for the 2012 periods presented, the Company applied the two-class method for calculating net (loss) income per share since it has issued securities, other than common stock, that contractually entitle the holder to participate in dividends and earnings of the Company. This calculation does not assume that preferred shares are converted into common shares. The undistributed earnings are allocated first to the preferred shareholders based on their contractual rights to dividends. This right is calculated on a pro rated basis for the portion of the period the preferred shares were outstanding. Any remaining undistributed earnings are allocated between preferred and common shares on a weighted average basis.

For periods in which the Company has a net loss, such as for the three months ended September 30, 2013 and the nine months ended September 30, 2013 and 2012, basic and diluted earnings per share are the same. Consequently, diluted earnings per share for these periods are not presented separately in the table below.

The computation for basic and diluted EPS was as follows (in thousands, except share and per share data):


	Three Months Ended September 30,							Nine Months Ended September 30,
	2013			2012							2013				2012
	(in thousands, except per share data)							(in thousands, except per share data)
Numerator for basic (loss) income per share:
Net (loss) income	$	(6,706)			$	11,142			$	(28,272		)	$	(80)
Accretion of redeemable convertible preferred stock		—				(900	)			(34,108		)		(2,700		)
Net income allocated to participating preferred shareholders		—				(4,271	)			—				—
Net (loss) income attributable to common shareholders	$	(6,706	)		$	5,971			$	(62,380		)	$	(2,780		)
Numerator for diluted income per share:
Net income					$	11,142
Accretion of redeemable convertible preferred stock						(900	)
Net income allocated to participating preferred shareholders						(4,271	)
Net income attributable to common shareholders					$	5,971
Denominator for basic and diluted loss (income) per share:
Weighted average shares for basic EPS		25,866,109				1,529,442				16,911,592				1,524,489
Weighted average effect of dilutive securities						51,404,514
Weighted average shares for diluted EPS						52,933,956
Basic EPS	$	(0.26	)		$	6.70			$	(3.69		)	$	(1.82		)
Diluted EPS	$	(0.26	)		$	0.11			$	(3.69		)	$	(1.82		)

Potentially dilutive securities excluded from the calculation of diluted net (loss) income per share attributable to common shareholders because to do so would be anti-dilutive were 3,253,638 and 11,304,141 for the three months ended September 30, 2013 and 2012, respectively, and 6,153,403 and 11,302,008 for the nine months ended September 30, 2013 and 2012, respectively.

Segments

The Company operates in only one segment. The chief operating decision-maker, who is the Company’s Chief Executive Officer, and management use cash flows as the primary measure to manage the business and do not segment the business for internal reporting or decision making.

Impact of Recently Issued Accounting Standards

On February 5, 2013, the Financial Accounting Standards Board issued an amendment ASU 2013-2, “Comprehensive Income (Topic 220)” (ASU 2013-02) to the disclosure requirements for reporting reclassifications out of accumulated other comprehensive income (AOCI). ASU 2013-02 was effective for the first interim or annual period beginning after December 15, 2012. The amendment requires companies to present information about reclassification adjustments from accumulated other comprehensive income to the income statement, including the income statement line items affected by the reclassification. The information must be presented in the financial statements in a single note or on the face of the financial statements. The new accounting guidance also requires the disclosure to be cross referenced to other financial statement disclosures for reclassification items that are not reclassified directly to net income in their entirety in the same reporting period. The Company adopted ASU 2013-02 in the first quarter of 2013. There was no material impact to the Company’s consolidated financial position, results of operations or cash flows upon adoption of this guidance.

Investments

9 Months Ended

Sep. 30, 2013

Investments [Abstract]

Investments

2. Investments

The following table summarizes available-for-sale securities:


	September 30, 2013
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
	(in thousands)
Corporate bonds	$	1,004	$	—	$	—	$	1,004
Commercial paper		—		—		—		—
Total	$	1,004	$	—	$	—	$	1,004

	December 31, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses				Estimated Fair Value
	(in thousands)
Corporate bonds	$	8,353	$	—	$	(2	)	$	8,351
Commercial paper		1,498		—		—			1,498
Total	$	9,851	$	—	$	(2	)	$	9,849

All of the Company’s investments as of September 30, 2013 and December 31, 2012 had maturities of one year or less.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Debt Security
-URI http://asc.fasb.org/extlink&oid=6509901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Equity Security
-URI http://asc.fasb.org/extlink&oid=6511694

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3, 19, 20, 21, 22, 137
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Property and Equipment

9 Months Ended

Sep. 30, 2013

Property and Equipment [Abstract]

Property and Equipment

3. Property and Equipment

Property and equipment consist of the following:


	September 30, 2013			December 31, 2012
	(in thousands)
Lab equipment	$	1,032		$	958
Leasehold improvements		78			78
Computer equipment		429			393
Office furniture and equipment		227			212
		1,766			1,641
Less accumulated depreciation		(1,431	)		(1,234	)
	$	335		$	407

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Loan Payable	9 Months Ended
Loan Payable	Sep. 30, 2013
Loan Payable [Abstract]
Loan Payable	4. Loan Payable On January 27, 2012, the Company entered into a Loan and Security Agreement (LSA) with Silicon Valley Bank (SVB) and MidCap Financial SBIC, LP (MidCap) allowing for borrowings up to $15.0 million, split between a first tranche of $3.0 million borrowed at the time of the agreement, and a second tranche of up to $12.0 million that would be available to be drawn by December 31, 2012 upon meeting one of three stated financial and/or operational goals. The first tranche was used to repay the remaining principal balance outstanding of $2.6 million under a previous loan. This repayment was deemed a modification of debt and therefore the remaining related deferred financing costs totaling $0.1 million remained in deferred financing costs and are being amortized over the term of the LSA through interest expense. The first tranche has an interest-only period of twelve months followed by a 30-month principal and interest amortization period with interest being charged at 8.25% per year for the full period of the LSA. The Company met one of the financial and/or operational goals mentioned above and, in September 2012, the remaining $12.0 million was borrowed in the second tranche. The second tranche has a six-month interest-only period followed by a 32 month principal and interest amortization period with interest being charged at the same rate as the first tranche. There are certain fees in accordance with the LSA which are being recorded as discounts or other long and short-term liabilities depending on the nature of the fees. The fees are being accreted through interest expense. Approximately $34,000 and $31,000 was included in interest expense for the three months ended September 30, 2013 and 2012, respectively. Approximately $109,000 and $111,000 was included in interest expense for the nine months ended September 30, 2013 and 2012, respectively. Concurrently with entering into the LSA, the Company also granted SVB a warrant to purchase shares of Series F preferred stock at a price of $2.045 per share equal to 2% of the aggregate amount of the advances made to the Company pursuant to the LSA, divided by the exercise price. In relation to the first tranche, the warrant became exercisable to purchase an aggregate of 29,340 shares of Series F preferred stock, and in relation to the second tranche, the warrant became exercisable to purchase an additional 117,360 shares of Series F preferred stock. As discussed in Note 1, the warrant is classified as a liability and is required to be measured at fair value. Therefore, the warrant was recorded as a debt discount at its fair value at the time of grant and accreted over the life of the LSA using the effective interest method. The subsequent re-valuation of the warrant (at fair value) resulted in no expense for the three months ended September 30, 2013 and 2012, and other expense of $171,000 and $28,000 for the nine months ended September 30, 2013 and 2012, respectively. Upon the completion of the Company’s IPO, this warrant was converted into a warrant to purchase 41,323 shares of common stock. In May 2013, SVB exercised the warrant in full and it is no longer outstanding.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2013
Commitments and Contingencies [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Leases The Company leases its facilities and certain office equipment under long-term non-cancelable operating leases that expire at various dates through 2018. Rent expense under non-cancelable operating leases and other month-to-month equipment rental agreements, including common area maintenance fees, totaled approximately $0.1 million and $0.1 million for the three months ended September 30, 2013 and 2012, respectively, and approximately $0.4 million and $0.3 million for the nine months ended September 30, 2013 and 2012, respectively. Significance of Revenue Source The Company is the recipient of federal research contract funds from BARDA. Periodic audits are required under the grant and contract agreements and certain costs may be questioned as appropriate under the agreements. Management believes that such amounts in the current year, if any, are not significant. Accordingly, no provision for refundable amounts under the agreements has been made as of September 30, 2013 and December 31, 2012.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Redeemable Convertible Preferred Stock

9 Months Ended

Sep. 30, 2013

Redeemable Convertible Preferred Stock [Abstract]

Redeemable Convertible Preferred Stock

6. Redeemable Convertible Preferred Stock

In February 2011, the Company issued 22,004,895 shares of $0.001 par value Series F redeemable convertible preferred stock at $2.045 per share and warrants to purchase an aggregate of 5,501,215 shares of Series F redeemable convertible preferred stock at an exercise price of $2.045 per share for proceeds of $45.0 million, less issuance costs of $0.2 million. Upon the completion of the Company’s IPO, these warrants were converted into warrants to purchase an aggregate of 1,549,628 shares of common stock at an exercise price of $7.26 per share. The warrants are exercisable at any time and expire on February 4, 2018.

In January 2012, the Company issued a warrant to SVB to purchase a number of shares of Series F redeemable convertible preferred stock at an exercise price of $2.045 per share equal to 2% of the aggregate amount of the advances made to the Company pursuant to the LSA, divided by the exercise price. Following the first and second tranches of the LSA, the warrant was exercisable to purchase an aggregate of 146,700 shares of Series F redeemable convertible preferred stock. Upon the completion of the Company’s IPO, this warrant was converted into a warrant to purchase 41,323 shares of common stock at an exercise price of $7.26 per share. In May 2013, SVB exercised the warrant in full and it is no longer outstanding.

The following table summarizes the authorized, issued and outstanding shares of redeemable convertible preferred stock as of December 31, 2012:


	Authorized Shares		Issued and Outstanding Shares
Series A		800,000		800,000
Series B		2,233,879		2,233,879
Series B-1		2,054,333		2,033,333
Series C		5,141,690		5,141,690
Series D		11,354,526		11,295,846
Series E		7,894,871		7,894,871
Series F		40,200,000		22,004,895
Total Shares		69,679,299		51,404,514

Upon the completion of the Company’s IPO in April 2013, the Company’s outstanding shares of redeemable convertible preferred stock and dividends accrued on Series F redeemable convertible preferred stock were automatically converted into an aggregate of 15,556,091 shares of common stock.

Warrants

The following warrants for the purchase of preferred stock on a one-to-one basis were issued, outstanding and exercisable at December 31, 2012:

Class	Date	Shares		Price Per Share		Expiration
Series B-1	November 5, 2003		21,000	$	1.500	November 2013
Series D	November 24, 2008		58,680	$	2.045	November 2018
Series F	February 7, 2011		5,501,215	$	2.045	February 2018
Series F	January 27, 2012		146,700	$	2.045	January 2022

As discussed in Note 1, the warrants exercisable for the Company’s Series F preferred stock were classified as a liability and were required to be measured at fair value. Therefore, such warrants were recorded at the full fair value with the Company’s Series F preferred stock being recorded at the residual value at the time of issuance. At each reporting date prior to the Company’s IPO, the warrants exercisable for the Company’s Series F preferred stock were recorded to fair value which was charged to other income. For the three months ended September 30, 2013 and 2012 there was no expense related to the valuation of the warrants. For the nine months ended September 30, 2013 and 2012, the Company recorded an expense of $6.4 million and $1.1 million, respectively, related to the valuation of the warrants. These amounts, coupled with the fair valuation of the warrants issued in relation to the Company’s LSA (see note 4), total to the fair value adjustments to warrant liability amount per the statements of operations and comprehensive loss.

Upon the completion of the Company’s IPO, all outstanding warrants to purchase redeemable convertible preferred stock were converted into warrants to purchase 1,613,395 shares of common stock and are no longer required to be measured at fair value. On April 16, 2013, a warrant was exercised to purchase 211,783 shares of the Company’s common stock. The Company received proceeds of $1.5 million in connection with such exercise. On May 24, 2013, a warrant was net exercised which resulted in the issuance of 37,600 shares of the Company’s common stock.

The following warrants for the purchase of common stock were issued, outstanding and exercisable at September 30, 2013:

Class

Date

Price Per Share

Expiration

Common

November 5, 2003

5,915

5.33

November 2013

Common

February 7, 2011

1,337,845

7.26

February 2018

Stockholders' Equity (Deficit)

9 Months Ended

Sep. 30, 2013

Stockholders' Equity (Deficit) [Abstract]

Stockholders' Equity (Deficit)

7. Stockholders’ Equity (Deficit)

Common Stock

The Company’s common stock consists of 200.0 million and 89.7 million authorized shares at September 30, 2013 and December 31, 2012, respectively, and 26.0 million and 1.5 million shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively.

Shares Reserved for Future Issuance

The following shares of common stock reserved for future issuances:


	September 30, 2013		December 31, 2012

Conversion of preferred stock and preferred stock warrants		—		16,093,483
Exercise of common stock warrants		1,343,760		—
Stock options issued and outstanding		2,492,940		2,593,423
Restricted Stock units outstanding		102,547		43,199
Authorized for future purchases under the 2013 Employee Stock Purchase Plan		704,225		—
Authorized for future grants under the 2013 Equity Incentive Plan		1,719,525		—
Authorized for future grants under the 2012 Equity Incentive Plan		—		427,933
		6,362,997		19,158,038

Stock Options

In connection with the Company’s IPO, the Company adopted the 2013 Equity Incentive Plan (the 2013 Plan). The 2013 Plan provides for the grant of incentive stock options (ISOs), nonstatutory stock options (NSOs), stock appreciation rights, restricted stock awards, restricted stock unit (RSU) awards, performance-based stock awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to employees, including officers, non-employee directors and consultants of the Company and its affiliates. Additionally, the 2013 Plan provides for the grant of performance cash awards. ISOs may be granted only to employees. All other awards may be granted to employees, including officers, and to non-employee directors and consultants. Initially, the aggregate number of shares of common stock that may be issued pursuant to stock awards under the 2013 Plan is the sum of (i) 1,408,450 shares, plus (ii) 244,717 shares, which was the number of shares reserved for issuance under the 2012 Equity Incentive Plan (the 2012 Plan) at the time the 2013 Plan became effective, plus (iii) any shares subject to outstanding stock options or other stock awards that would have otherwise returned to the 2012 Plan (such as upon the expiration or termination of a stock award prior to vesting). Additionally, the number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year, beginning on January 1, 2014 and continuing through and including January 1, 2023, by 2.5% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors. The maximum number of shares that may be issued upon the exercise of ISOs under the 2013 Plan is 2,816,901 shares. Following the effectiveness of the 2013 Plan in April 2013, no further grants were made under the 2012 Plan.

The 2013 Plan has an “early exercise” provision under which options to purchase common stock may be exercised prior to being fully vested; however, the shares issued for options exercised under the “early exercise” provision continue to vest under the same terms as the underlying exercised option. Upon termination of an employee prior to the vesting of such shares, the Company can either repurchase the unvested shares or let the repurchase right expire.

In February 2013 the Company’s board of directors adopted the 2013 Employee Stock Purchase Plan (ESPP), which was subsequently ratified by stockholders and became effective in April 2013. The purpose of the ESPP is to retain the services of new employees and secure the services of new and existing employees while providing incentives for such individuals to exert maximum efforts toward the Company’s success and that of its affiliates. The ESPP authorizes the issuance of 704,225 shares of common stock pursuant to purchase rights granted to the Company’s employees or to employees of any of its designated affiliates. The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2014 through January 1, 2023 by the least of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 422,535 shares, or (c) a number determined by the Company’s board of directors that is less than (a) and (b). The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code of 1986. As of the date hereof, no shares of common stock have been purchased under the ESPP.

A summary of activity related to the Company’s stock options is as follows:

	Number of Options Outstanding			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (in Years)
Balance, December 31, 2012		2,593,423		$	2.45		7.36
Granted		241,313			9.63		—
Exercised		(217,338	)		2.68		—
Expired or Canceled		(2,816	)		1.56		—
Forfeited		(121,642	)		2.54		—
Balance, September 30, 2013		2,492,940		$	3.12		6.82
Exercisable at September 30, 2013		1,759,426		$	2.25		6.03
Vested or expected to vest at September 30, 2013		2,515,820		$	2.98		6.80

For awards with only service conditions and graded-vesting features, the Company recognizes compensation expense on a straight-line basis over the requisite service period. The fair value of options vested and share-based compensation expense recognized are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
	(in thousands)				(in thousands)
Research and development:
Employee	$	109	$	68	$	422	$	234
Non-employee		7		28		28		59
General and administrative:
Employee		100		459		350		781
Non-employee		48		39		125		59
	$	264	$	594	$	925	$	1,133

Restricted Stock Units

In 2013 and 2012, the Company issued RSUs to certain employees which vest based on specific performance criteria. By their terms, the RSUs became immediately vested upon the effective date of the registration statement for the Company’s common stock in connection with the IPO, subject to the continuous service with the Company at the vesting event. When vested, the RSU represents the right to be issued the number of shares of the Company’s common stock that is equal to the number of RSUs granted.

A summary of activity related to the Company’s RSUs is as follows:

	Number of Restricted Stock Units Outstanding
Balance, December 31, 2012		43,199
Granted		59,348
Balance, September 30, 2013		102,547

In April 2013, $1.9 million in compensation expense had been recorded as the performance criterion was met upon the completion of the Company’s IPO.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2013
Income Taxes [Abstract]
Income Taxes	8. Income Taxes The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2013 as the Company incurred losses for the nine month period ended September 30, 2013 and is forecasting additional losses through the 4th quarter, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2013. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740. Due to the Company's history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a valuation allowance, since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. At September 30, 2013, the Company had no unrecognized tax benefits that would reduce the Company’s effective tax rate if recognized.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

Significant Agreements	9 Months Ended
Significant Agreements	Sep. 30, 2013
Significant Agreements [Abstract]
Significant Agreements	9. Significant Agreements The Regents of the University of California In May 2002, the Company entered into a license agreement with The Regents of the University of California (UC) under which the Company obtained an exclusive, worldwide license to UC’s patent rights in certain inventions (the UC Patent Rights) related to lipid-conjugated antiviral compounds and their use, including certain patents relating to brincidofovir and CMX157. The license agreement was amended in September 2002 in order to expand the scope of the license and again in December 2010 in order to modify certain financial terms. The agreement was amended a third time in September 2011 to add additional patents related to certain metabolically stable lipid-conjugate compounds. A fourth amendment was executed in July 2012 to alter the rights and obligations of the parties in light of the Company’s current business plans. As partial consideration for the rights granted to the Company under the license agreement, the Company is required to pay certain cash milestone payments in connection with the development and commercialization of compounds that are covered by the UC Patent Rights. In connection with the development and commercialization of brincidofovir and CMX157, the Company could be required to pay UC up to an aggregate of $3.4 million in milestone payments, assuming the achievement of all applicable milestone events under the license agreement. Under the license agreement, the Company is permitted to research, develop, manufacture and commercialize products utilizing the UC Patent Rights for all human and veterinary uses, and to sublicense such rights. UC retained the right, on behalf of itself and other non-profit institutions, to use the UC Patent Rights for educational and research purposes and to publish information about the UC Patent Rights. In consideration for the rights granted under the license agreement, the Company has issued UC an aggregate of 64,788 shares of common stock. As additional consideration, the Company is required to pay certain cash milestone payments in connection with the development and commercialization of compounds that are covered by the UC Patent Rights, plus certain annual fees to maintain such patents until the Company commercializes a product utilizing UC Patent Rights. In addition, upon commercialization of any product utilizing the UC Patent Rights (which would include the commercialization of brincidofovir or CMX157), the Company will be required to pay low single digit royalties on net sales of such product. In the event the Company sublicenses a UC Patent Right the Company is obligated to pay to UC a fee, which amount will vary depending upon the size of any upfront payment the Company receives and the clinical development stage of the compound being sublicensed, but which could be up to approximately 50% of the sublicense fee in certain circumstances. With respect to brincidofovir or CMX157, the fee payable to UC will not exceed 5% and 10% of the sublicense fee, respectively. In addition, the Company will also be required to pay to UC a low single digit sublicense royalty on net sales of products that use the sublicensed UC Patent Rights, but in no event will the Company be required to pay more than 50% of the royalties it receives in connection with the relevant sublicense. Any such royalty payment will be reduced by other payments the Company is required to make to third parties until a minimum royalty has been reached. As a result of meeting certain milestones and sublicense fees related to the license agreement, the Company recognized expenses of $0.9 million for the year ended December 31, 2012. The Company did not recognize expenses under this agreement for the three or nine months ended September 30, 2013. Biomedical Advanced Research and Development Authority (BARDA) In February 2011, the Company entered into a contract with BARDA for the advanced development of brincidofovir as a medical countermeasure in the event of a smallpox release. The contract has been amended several times, most recently on May 30, 2013, to extend the contract into the first option segment period of performance. Under the contract, BARDA will reimburse the Company, plus pay a fixed fee, for the research and development of brincidofovir as a broad-spectrum therapeutic antiviral for the treatment of smallpox infections. The contract consists of an initial performance period, referred to as the base performance segment, plus up to four extension periods of approximately one year each, referred to as option segments, each of which may be exercised at BARDA’s sole discretion. The Company must complete the agreed upon milestones and deliverables in each discrete work segment before the next option segment is eligible to be exercised. Under the contract as currently in effect, the Company may receive up to $75.8 million in expense reimbursement and $5.3 million in fees. The Company is currently performing under the first option segment of the contract during which the Company may receive up to a total of $5.0 million in expense reimbursement and fees. The term of the first option segment is 12 months and is scheduled to end on May 30, 2014. Merck, Sharp & Dohme Corp. In July 2012, the Company entered into a collaboration and license agreement granting Merck exclusive worldwide rights to CMX157, the Company’s lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection. Under the terms of the agreement, Merck received an exclusive worldwide license for any human use of CMX157 and has agreed to use commercially reasonable efforts to develop and commercialize CMX157 in the United States and at least three major European markets. Following execution of the agreement, the Company received a $17.5 million upfront payment from Merck. As additional consideration, the Company is eligible to receive up to a total of $151.0 million in milestone payments if certain development and regulatory milestones are achieved by Merck for products utilizing CMX157, as well as tiered royalties on net sales ranging from high single digits to low double digits, depending upon the volume of sales of each applicable product, if CMX157 is successfully commercialized. Milestone payments are triggered upon the completion of various stages of the regulatory approval process for each of the first two indications for CMX157, with the final milestones reached upon approval in the United States and three major European markets. Royalties for any given product will continue on a country-by-country basis through the later of the expiration of the Company’s patent rights applicable to such product or ten years from the first commercial sale of such product. The Company’s participation in the collaboration with Merck, including its involvement in the joint steering committee to monitor the development of CMX157, represents a right and an observation role only, rather than a substantive performance obligation. As such, the Company’s performance in this collaboration relates to the specific transfers in connection with the license which was completed during the same quarter the agreement was entered into. Therefore, the Company recognized the upfront payment during the year ended December 31, 2012. The contingent event-based payments that the Company may receive pursuant to the agreement do not meet the definition of a milestone as achievement of the triggering event for such payments is based on the performance of Merck and not Chimerix. Therefore, the milestone method will not be applied to those payments.

The Business and Summary of Significant Accounting Policies (Policy)

9 Months Ended

Sep. 30, 2013

The Business and Summary of Significant Accounting Policies [Abstract]

Description Of Business

Description of Business

Reclassifications

Cash And Cash Equivalents

Cash and Cash Equivalents

The Company considers any highly liquid instrument with an original maturity of three months or less at acquisition to be a cash equivalent. Cash equivalents consist of money market accounts.

Investments

Concentration Of Credit Risk

Concentration of Credit Risk

Accounts Receivable

Fair Value Of Financial Instruments

Fair Value of Financial Instruments



Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.



Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

There was no material re-measurement to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis.

Below is a table that presents information about certain assets and liabilities measured at fair value on a recurring basis:


			Fair Value Measurements at September 30, 2013
	September 30, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
	(in thousands)
Cash equivalents	$	113,816	$	113,816	$	—	$	—
Short-term investments		1,004		—		1,004		—


			Fair Value Measurements at December 31, 2012
	December 31, 2012		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
	(in thousands)
Cash equivalents	$	17,687	$	16,381	$	1,306	$	—
Short-term investments		9,849		—		9,849		—
Redeemable convertible preferred stock warrant liability		7,512		—		—		7,512

Below is a table that presents a reconciliation of the beginning and ending balances of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3):


	Fair Value Measurements (Level 3)
	(in thousands)
Redeemable Convertible Preferred Stock Warrant Liability
Balance at January 1, 2012	$	6,491
Issuance		174
Fair value increase recorded in other expense		847
Fair value at December 31, 2012		7,512
Fair value increase recorded in other expense		6,590
Reclassification of warrant liability to additional paid-in capital		(14,102	)
Fair value at September 30, 2013	$	—

Property And Equipment

Property and Equipment

Impairment Of Long-Lived Assets

Impairment of Long-Lived Assets

Deferred Public Offering Costs

Deferred Rent

Revenue Recognition

Research and Development

Interest Expense, Net

Income Taxes

Share-Based Compensation

Basic And Dilutive Net Loss Per Share Of Common Stock

Basic and Dilutive Net (Loss) Income Per Share of Common Stock

The computation for basic and diluted EPS was as follows (in thousands, except share and per share data):


	Three Months Ended September 30,							Nine Months Ended September 30,
	2013			2012							2013				2012
	(in thousands, except per share data)							(in thousands, except per share data)
Numerator for basic (loss) income per share:
Net (loss) income	$	(6,706)			$	11,142			$	(28,272		)	$	(80)
Accretion of redeemable convertible preferred stock		—				(900	)			(34,108		)		(2,700		)
Net income allocated to participating preferred shareholders		—				(4,271	)			—				—
Net (loss) income attributable to common shareholders	$	(6,706	)		$	5,971			$	(62,380		)	$	(2,780		)
Numerator for diluted income per share:
Net income					$	11,142
Accretion of redeemable convertible preferred stock						(900	)
Net income allocated to participating preferred shareholders						(4,271	)
Net income attributable to common shareholders					$	5,971
Denominator for basic and diluted loss (income) per share:
Weighted average shares for basic EPS		25,866,109				1,529,442				16,911,592				1,524,489
Weighted average effect of dilutive securities						51,404,514
Weighted average shares for diluted EPS						52,933,956
Basic EPS	$	(0.26	)		$	6.70			$	(3.69		)	$	(1.82		)
Diluted EPS	$	(0.26	)		$	0.11			$	(3.69		)	$	(1.82		)

Segments

The Business and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2013

The Business and Summary of Significant Accounting Policies [Abstract]

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Below is a table that presents information about certain assets and liabilities measured at fair value on a recurring basis:


			Fair Value Measurements at September 30, 2013
	September 30, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
	(in thousands)
Cash equivalents	$	113,816	$	113,816	$	—	$	—
Short-term investments		1,004		—		1,004		—


			Fair Value Measurements at December 31, 2012
	December 31, 2012		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
	(in thousands)
Cash equivalents	$	17,687	$	16,381	$	1,306	$	—
Short-term investments		9,849		—		9,849		—
Redeemable convertible preferred stock warrant liability		7,512		—		—		7,512

Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis

Below is a table that presents a reconciliation of the beginning and ending balances of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3):


	Fair Value Measurements (Level 3)
	(in thousands)
Redeemable Convertible Preferred Stock Warrant Liability
Balance at January 1, 2012	$	6,491
Issuance		174
Fair value increase recorded in other expense		847
Fair value at December 31, 2012		7,512
Fair value increase recorded in other expense		6,590
Reclassification of warrant liability to additional paid-in capital		(14,102	)
Fair value at September 30, 2013	$	—

Schedule of Prepaid and Other Current Assets

Prepaid and other current assets consist of the following:


	September 30, 2013		December 31, 2012
	(in thousands)
Prepaid development expenses	$	2,241	$	486
Deferred public offering costs		—		273
Other prepaid and other current assets		442		224
	$	2,683	$	983

Schedule of Accrued Liabilities

Accrued liabilities consist of the following:


	September 30, 2013		December 31, 2012
	(in thousands)
Accrued compensation	$	565		$	560
Accrued development expenses		568			98
Other accrued liabilities		468			248
	$	1,601		$	906

Schedule of Computation for Basic and Diluted EPS

The computation for basic and diluted EPS was as follows (in thousands, except share and per share data):


	Three Months Ended September 30,							Nine Months Ended September 30,
	2013			2012							2013				2012
	(in thousands, except per share data)							(in thousands, except per share data)
Numerator for basic (loss) income per share:
Net (loss) income	$	(6,706)			$	11,142			$	(28,272		)	$	(80)
Accretion of redeemable convertible preferred stock		—				(900	)			(34,108		)		(2,700		)
Net income allocated to participating preferred shareholders		—				(4,271	)			—				—
Net (loss) income attributable to common shareholders	$	(6,706	)		$	5,971			$	(62,380		)	$	(2,780		)
Numerator for diluted income per share:
Net income					$	11,142
Accretion of redeemable convertible preferred stock						(900	)
Net income allocated to participating preferred shareholders						(4,271	)
Net income attributable to common shareholders					$	5,971
Denominator for basic and diluted loss (income) per share:
Weighted average shares for basic EPS		25,866,109				1,529,442				16,911,592				1,524,489
Weighted average effect of dilutive securities						51,404,514
Weighted average shares for diluted EPS						52,933,956
Basic EPS	$	(0.26	)		$	6.70			$	(3.69		)	$	(1.82		)
Diluted EPS	$	(0.26	)		$	0.11			$	(3.69		)	$	(1.82		)

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

Investments (Tables)

9 Months Ended

Sep. 30, 2013

Investments [Abstract]

Summary of Available-for-Sale Securities

The following table summarizes available-for-sale securities:


	September 30, 2013
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
	(in thousands)
Corporate bonds	$	1,004	$	—	$	—	$	1,004
Commercial paper		—		—		—		—
Total	$	1,004	$	—	$	—	$	1,004

	December 31, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses				Estimated Fair Value
	(in thousands)
Corporate bonds	$	8,353	$	—	$	(2	)	$	8,351
Commercial paper		1,498		—		—			1,498
Total	$	9,851	$	—	$	(2	)	$	9,849

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2013

Property and Equipment [Abstract]

Property and Equipment

Property and equipment consist of the following:


	September 30, 2013			December 31, 2012
	(in thousands)
Lab equipment	$	1,032		$	958
Leasehold improvements		78			78
Computer equipment		429			393
Office furniture and equipment		227			212
		1,766			1,641
Less accumulated depreciation		(1,431	)		(1,234	)
	$	335		$	407

Redeemable Convertible Preferred Stock (Tables)

9 Months Ended

Sep. 30, 2013

Summary of Authorized, Issued and Outstanding Shares of Redeemable Convertible Preferred Stock

The following table summarizes the authorized, issued and outstanding shares of redeemable convertible preferred stock as of December 31, 2012:


	Authorized Shares		Issued and Outstanding Shares
Series A		800,000		800,000
Series B		2,233,879		2,233,879
Series B-1		2,054,333		2,033,333
Series C		5,141,690		5,141,690
Series D		11,354,526		11,295,846
Series E		7,894,871		7,894,871
Series F		40,200,000		22,004,895
Total Shares		69,679,299		51,404,514

Common Stock [Member]

Schedule of Warrants Issued, Outstanding and Exercisable

The following warrants for the purchase of common stock were issued, outstanding and exercisable at September 30, 2013:

Class

Date

Price Per Share

Expiration

Common

November 5, 2003

5,915

5.33

November 2013

Common

February 7, 2011

1,337,845

7.26

February 2018

Redeemable Convertible Preferred Stock [Member]

Schedule of Warrants Issued, Outstanding and Exercisable

The following warrants for the purchase of preferred stock on a one-to-one basis were issued, outstanding and exercisable at December 31, 2012:

Class	Date	Shares		Price Per Share		Expiration
Series B-1	November 5, 2003		21,000	$	1.500	November 2013
Series D	November 24, 2008		58,680	$	2.045	November 2018
Series F	February 7, 2011		5,501,215	$	2.045	February 2018
Series F	January 27, 2012		146,700	$	2.045	January 2022

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

- Definition

Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References + Details

Stockholders' Equity (Deficit) (Tables)

9 Months Ended

Sep. 30, 2013

Stockholders' Equity (Deficit) [Abstract]

Schedule of Shares Reserved for Future Issuance

The following shares of common stock reserved for future issuances:


	September 30, 2013		December 31, 2012

Conversion of preferred stock and preferred stock warrants		—		16,093,483
Exercise of common stock warrants		1,343,760		—
Stock options issued and outstanding		2,492,940		2,593,423
Restricted Stock units outstanding		102,547		43,199
Authorized for future purchases under the 2013 Employee Stock Purchase Plan		704,225		—
Authorized for future grants under the 2013 Equity Incentive Plan		1,719,525		—
Authorized for future grants under the 2012 Equity Incentive Plan		—		427,933
		6,362,997		19,158,038

Summary of Activity Related to Stock Options

A summary of activity related to the Company’s stock options is as follows:

	Number of Options Outstanding			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (in Years)
Balance, December 31, 2012		2,593,423		$	2.45		7.36
Granted		241,313			9.63		—
Exercised		(217,338	)		2.68		—
Expired or Canceled		(2,816	)		1.56		—
Forfeited		(121,642	)		2.54		—
Balance, September 30, 2013		2,492,940		$	3.12		6.82
Exercisable at September 30, 2013		1,759,426		$	2.25		6.03
Vested or expected to vest at September 30, 2013		2,515,820		$	2.98		6.80

Fair Value of Option Vested and Share-Based Compensation Expense

The fair value of options vested and share-based compensation expense recognized are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
	(in thousands)				(in thousands)
Research and development:
Employee	$	109	$	68	$	422	$	234
Non-employee		7		28		28		59
General and administrative:
Employee		100		459		350		781
Non-employee		48		39		125		59
	$	264	$	594	$	925	$	1,133

Summary of Activity Related to Restricted Stock Units

A summary of activity related to the Company’s RSUs is as follows:

	Number of Restricted Stock Units Outstanding
Balance, December 31, 2012		43,199
Granted		59,348
Balance, September 30, 2013		102,547

The Business and Summary of Significant Accounting Policies (Narrative) (Details)				3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 23, 2013 shares	Apr. 10, 2013 USD ($) $ / shares shares	Mar. 25, 2013 item	Sep. 30, 2013 shares	Sep. 30, 2012 shares	Sep. 30, 2013 USD ($) shares	Sep. 30, 2012 shares	Dec. 31, 2012 USD ($) $ / shares
Description Of Business
Stock split, reverse description			the Company's board of directors approved and implemented a 3.55-for-1 reverse stock split of the Company's outstanding common stock
Reverse stock split, conversion ratio \| item			3.55
Proceeds from initial public offering						$ 107,634,000
Investments Related to Corporate Bonds and Commercial Paper
Available for sale securities losses, other-than-temporary						0		$ 0
Property And Equipment
Impairment of long-lived assets						$ 0
Deferred Public Offering Costs
Deferred public offering costs								$ 273,000
Per share information:
Anti-dilutive securities excluded from the calculation loss per share \| shares				3,253,638	11,304,141	6,153,403	11,302,008
Over Allotment Options [Member]
Description Of Business
Stock issued during the period, shares \| shares		1,098,000
Stock issued during the period, value		$ 14,300,000
Stock price, initial public offering \| $ / shares		$ 14.00
Public offering underwriting discounts and commissions		$ 1,100,000
IPO [Member]
Description Of Business
Stock issued during the period, shares \| shares		7,320,000
Stock price, initial public offering \| $ / shares		$ 14.00
Proceeds from initial public offering		$ 93,300,000
Public offering underwriting discounts and commissions		7,100,000
Offering expenses		$ 2,100,000
Secondary Offering [Member] \| Subsequent Event [Member]
Description Of Business
Stock issued during the period, shares \| shares	2,476,995
Series F [Member]
Fair Value Of Financial Instruments
Fair value \| $ / shares		$ 3.94
Series F [Member] \| IPO [Member]
Description Of Business
Conversion of stock, shares converted \| shares		15,556,091
Warrant [Member]
Fair Value Of Financial Instruments
Volatility		79.00%						79.00%
Expected term		2 years 6 months
Risk free interest rate		0.24%
Dividend yield		0.00%
Warrant [Member] \| IPO [Member]
Description Of Business
Conversion of stock, shares converted \| shares		1,613,395
Maximum [Member]
Property And Equipment
Property and equipment, useful life						5 years
Maximum [Member] \| Series F [Member]
Fair Value Of Financial Instruments
Fair value \| $ / shares								$ 2.85
Maximum [Member] \| Warrant [Member]
Fair Value Of Financial Instruments
Expected term								5 years
Expected liquidity								31.00%
Minimum [Member]
Property And Equipment
Property and equipment, useful life						3 years
Minimum [Member] \| Series F [Member]
Fair Value Of Financial Instruments
Fair value \| $ / shares								$ 2.19
Minimum [Member] \| Warrant [Member]
Fair Value Of Financial Instruments
Expected term								8 months
Expected liquidity								2.00%

The Business and Summary of Significant Accounting Policies (Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Liabilities, fair value		$ 7,512	$ 6,491
Level 3 [Member]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Liabilities, fair value		7,512
Cash and Cash Equivalents [Member]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Assets, fair value	$ 113,816	17,687
Cash and Cash Equivalents [Member] \| Level 1 [Member]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Assets, fair value	113,816	16,381
Cash and Cash Equivalents [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Assets, fair value		1,306
Cash and Cash Equivalents [Member] \| Level 3 [Member]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Assets, fair value
Short-term Investments [Member]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Assets, fair value	1,004	9,849
Short-term Investments [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Assets, fair value	$ 1,004	$ 9,849
Short-term Investments [Member] \| Level 3 [Member]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Assets, fair value

The Business and Summary of Significant Accounting Policies (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
The Business and Summary of Significant Accounting Policies [Abstract]
Beginning of period	$ 7,512	$ 6,491
Issuance		174
Fair value increase recorded in other expense	6,590	847
Reclassification of warrant liability to additional paid-in captial	$ (14,102)
Ending period		$ 7,512

The Business and Summary of Significant Accounting Policies (Schedule of Prepaid and Other Current Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
The Business and Summary of Significant Accounting Policies [Abstract]
Prepaid development expenses	$ 2,241	$ 486
Deferred public offering costs		273
Other prepaid and other current assets	442	224
Prepaid and other current assets, total	$ 2,683	$ 983

The Business and Summary of Significant Accounting Policies (Schedule of Accrued Liabilties) (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
The Business and Summary of Significant Accounting Policies [Abstract]
Accrued compensation	$ 565	$ 560
Accrued development expenses	568	98
Other accrued liabilities	468	248
Accrued liabilities, current, total	$ 1,601	$ 906

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

The Business and Summary of Significant Accounting Policies (Schedule of Computation of Basic and Diluted EPS) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator for basic (loss) income per share:
Net (loss) income	$ (6,706)	$ 11,142	$ (28,272)	$ (80)
Accretion of redeemable convertible preferred stock		(900)	(34,108)	(2,700)
Net income allocated to participating preferred shareholders		(4,271)
Net (loss) income attributable to common shareholders	(6,706)	5,971	(62,380)	(2,780)
Numerator for diluted income per share:
Net (loss) income	(6,706)	11,142	(28,272)	(80)
Accretion of redeemable convertible preferred stock		(900)	(34,108)	(2,700)
Net income allocated to participating preferred shareholders		(4,271)
Net (loss) income attributable to common shareholders	$ (6,706)	$ 5,971	$ (62,380)	$ (2,780)
Denominator for basic and diluted loss (income) per share:
Weighted average shares for basic EPS	25,866,109	1,529,442	16,911,592	1,524,489
Weighted average effect of dilutive securities		51,404,514
Weighted average shares for diluted EPS	25,866,109	52,933,956	16,911,592	1,524,489
Basic EPS	$ (0.26)	$ 6.70	$ (3.69)	$ (1.82)
Diluted EPS	$ (0.26)	$ 0.11	$ (3.69)	$ (1.82)

Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Schedule of Investments [Line Items]
Amortized cost	$ 1,004	$ 9,851
Gross unrealized gains
Gross unrealized losses		(2)
Estimated fair value	$ 1,004	$ 9,849
Investments maturity period, maximum	1 year	1 year
Corporate Bonds [Member]
Schedule of Investments [Line Items]
Amortized cost	$ 1,004	$ 8,353
Gross unrealized gains
Gross unrealized losses		(2)
Estimated fair value	$ 1,004	8,351
Commercial Paper [Member]
Schedule of Investments [Line Items]
Amortized cost		1,498
Gross unrealized gains
Estimated fair value		$ 1,498

- Definition

Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=7534914&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 17
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15C
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section A
-Paragraph 4, 5
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,766	$ 1,641
Less accumulated depreciation	(1,431)	(1,234)
Property and equipment, net	335	407
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,032	958
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	78	78
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	429	393
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 227	$ 212

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References + Details

Loan Payable (Details)	3 Months Ended		9 Months Ended
Loan Payable (Details)	Sep. 30, 2013 USD ($) $ / item shares	Sep. 30, 2012 USD ($)	Sep. 30, 2013 USD ($) $ / item shares	Sep. 30, 2012 USD ($)	Jan. 27, 2012 USD ($)
Line of Credit Facility [Line Items]
Loan and security agreement, maximum capacity					$ 15,000,000
Interest expense	$ 270,000	$ 130,000	$ 1,041,000	$ 367,000
Preferred stock, strike price \| $ / item	2.045		2.045
Aggregate amount of advances, percentage			2.00%
Other expenses	$ 0	0	$ 171,000	28,000
Warrants to purchase common stock \| shares	41,323		41,323
Second Tranche [Member]
Line of Credit Facility [Line Items]
Loan and security agreement, remaining capacity					12,000,000
Interest only period			6 months
Principal and interest amortization period			32 months
Warrants to purchase common stock \| shares	117,360		117,360
First Tranche [Member]
Line of Credit Facility [Line Items]
Loan and security agreement, outstanding					$ 3,000,000
Loan payment			$ 2,600,000
Deferred financing costs	$ 100,000		$ 100,000
Interest only period			12 months
Principal and interest amortization period			30 months
Loan and security agreement, interest rate			8.25%
Warrants to purchase common stock \| shares	29,340		29,340
Loan And Security Agreement [Member]
Line of Credit Facility [Line Items]
Interest expense	$ 34,000	$ 31,000	$ 109,000	$ 111,000

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Commitments and Contingencies [Abstract]
Operating leases, rent expense	$ 0.1	$ 0.1	$ 0.4	$ 0.3

Redeemable Convertible Preferred Stock (Narrative) (Details) $ / shares in Units, $ in Thousands								3 Months Ended		9 Months Ended
	May 24, 2013 shares	Apr. 16, 2013 USD ($) shares	Apr. 10, 2013 $ / item shares	Jan. 27, 2012 $ / shares shares	Feb. 07, 2011 USD ($) $ / shares $ / item shares	Feb. 07, 2011 $ / shares $ / item shares	Nov. 05, 2003 $ / item	Sep. 30, 2013 USD ($) $ / item	Sep. 30, 2012 USD ($)	Sep. 30, 2013 USD ($) $ / item	Sep. 30, 2012 USD ($)	May 31, 2013 shares	Dec. 31, 2012 shares
Redeemable convertible preferred stock issued													51,404,514
Aggregate number of common shares converted from redeemable convertible preferred stock			15,556,091
Proceeds from exercise of warrants \| $										$ 1,537
Warrants exercise price \| $ / item								2.045		2.045
Silicon Valley Bank [Member]
Warrants outstanding												0
IPO Completion [Member]
Warrants expiration date			Feb. 04, 2018
Warrants exercise price \| $ / item			7.26
Series F [Member]
Redeemable convertible preferred stock issued					22,004,895	22,004,895							22,004,895
Redeemable convertible preferred stock issued, par value per share \| $ / shares					$ 0.001	$ 0.001
Redeemable convertible preferred stock issued, redemption price per share \| $ / shares				$ 2.045	$ 2.045	$ 2.045
Redeemable convertible preferred stock, warrants issued				146,700	5,501,215
Redeemable convertible preferred stock, warrants issued, issuance costs \| $					$ 200
Proceeds from issuance of redeemable preferred stock \| $					$ 45,000
Warrants expiration date				Jan. 22, 2022	Feb. 04, 2018
Series F [Member] \| Silicon Valley Bank [Member]
Redeemable convertible preferred stock issued, redemption price per share \| $ / shares				$ 2.045
Redeemable convertible preferred stock, warrants issued				146,700
Percentage of the aggregate amount of advances made				2.00%
Series F [Member] \| IPO Completion [Member]
Redeemable convertible preferred stock, warrants issued			1,549,628
Warrant [Member]
Other expense as a result of fair valuation of warrants \| $								$ 0	$ 0	$ 6,400	$ 1,100
Warrant [Member] \| Silicon Valley Bank [Member]
Redeemable convertible preferred stock, warrants issued			41,323
Warrants exercise price \| $ / item			7.26
Warrant [Member] \| IPO [Member]
Class of warrant or rights exercised		211,783
Proceeds from exercise of warrants \| $		$ 1,500
Warrant [Member] \| IPO Completion [Member]
Redeemable convertible preferred stock, warrants issued			1,613,395
Common Stock [Member]
Warrants expiration date						Feb. 01, 2018	Nov. 01, 2013
Class of warrant or rights exercised	37,600
Warrants exercise price \| $ / item					7.26	7.26	5.33

Redeemable Convertible Preferred Stock (Summary of Authorized, Issued and Outstanding Shares of Redeemable Convertible Preferred Stock) (Details) - shares	Dec. 31, 2012	Feb. 07, 2011
Authorized shares	69,679,299
Issued and outstanding shares	51,404,514
Series A [Member]
Authorized shares	800,000
Issued and outstanding shares	800,000
Series B [Member]
Authorized shares	2,233,879
Issued and outstanding shares	2,233,879
Series B-1 [Member]
Authorized shares	2,054,333
Issued and outstanding shares	2,033,333
Series C [Member]
Authorized shares	5,141,690
Issued and outstanding shares	5,141,690
Series D [Member]
Authorized shares	11,354,526
Issued and outstanding shares	11,295,846
Series E [Member]
Authorized shares	7,894,871
Issued and outstanding shares	7,894,871
Series F [Member]
Authorized shares	40,200,000
Issued and outstanding shares	22,004,895	22,004,895

- Definition

The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References + Details

Redeemable Convertible Preferred Stock (Schedule of Warrants Issued, Outstanding and Exercisable) (Details)	Jan. 27, 2012 $ / shares shares	Feb. 07, 2011 $ / shares $ / item shares	Feb. 07, 2011 $ / shares $ / item shares	Nov. 24, 2008 $ / shares shares	Nov. 05, 2003 $ / shares $ / item shares	Nov. 05, 2003 $ / shares $ / item shares	Sep. 30, 2013 $ / item
Warrants exercise price \| $ / item							2.045
Series B-1 [Member]
Redeemable convertible preferred stock, warrants issued					21,000
Redeemable convertible preferred stock issued, redemption price per share \| $ / shares					$ 1.500	$ 1.500
Warrants expiration date					Nov. 01, 2013
Series D [Member]
Redeemable convertible preferred stock, warrants issued				58,680
Redeemable convertible preferred stock issued, redemption price per share \| $ / shares				$ 2.045
Warrants expiration date				Nov. 01, 2018
Series F [Member]
Redeemable convertible preferred stock, warrants issued	146,700		5,501,215
Redeemable convertible preferred stock issued, redemption price per share \| $ / shares	$ 2.045	$ 2.045	$ 2.045
Warrants expiration date	Jan. 22, 2022		Feb. 04, 2018
Common Stock [Member]
Warrants issued, outstanding and exercisable		1,337,845	1,337,845		5,915	5,915
Warrants exercise price \| $ / item		7.26	7.26		5.33	5.33
Warrants expiration date		Feb. 01, 2018				Nov. 01, 2013

- Definition

Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References + Details

Stockholders' Equity (Deficit) (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended		9 Months Ended
	Apr. 30, 2013	Feb. 28, 2013	Sep. 30, 2013	Apr. 10, 2013	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued			25,974,809		1,533,996
Common stock, shares outstanding			25,974,809		1,533,996
Common stock, shares authorized			200,000,000		89,700,000
Number of shares outstanding under the plan			2,492,940		2,593,423
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Compensation expense, allocated	$ 1.9
The 2012 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized to be granted				244,717	427,933
The 2013 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized to be granted			1,719,525	1,408,450
Percentage of total number of shares of capital stock outstanding			2.50%
The 2013 ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares outstanding under the plan			422,535
Number of shares authorized to be granted		704,225	704,225
Percentage of total number of shares of capital stock outstanding		1.00%
Maximum [Member] \| The 2013 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized to be granted			2,816,901

Stockholders' Equity (Deficit) (Schedule of Shares Reserved for Future Issuance) (Details) - shares	Sep. 30, 2013	Apr. 10, 2013	Feb. 28, 2013	Dec. 31, 2012
Conversion of preferred stock and preferred stock warrants				16,093,483
Exercise of common stock warrants	1,343,760
Stock options issued and outstanding	2,492,940			2,593,423
Restricted Stock units outstanding	102,547			43,199
Shares of common stock reserved for future issuance	6,362,997			19,158,038
The 2012 Plan [Member]
Authorized for future grants under the plan		244,717		427,933
The 2013 Plan [Member]
Authorized for future grants under the plan	1,719,525	1,408,450
The 2013 ESPP [Member]
Authorized for future grants under the plan	704,225		704,225

Stockholders' Equity (Deficit) (Summary of Activity Related to Stock Options) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Stockholders' Equity (Deficit) [Abstract]
Number of options outstanding, Beginning balance	2,593,423
Number of options outstanding, Granted	241,313
Number of options outstanding, Exercised	(217,338)
Number of options outstanding, Expired or Canceled	(2,816)
Number of options outstanding, Forfeited	(121,642)
Number of options outstanding, Ending balance	2,492,940	2,593,423
Number of options outstanding, Exercisable	1,759,426
Number of options outstanding, Vested and expected to vest	2,515,820
Weighted-average exercise price, beginning balance	$ 2.45
Weighted-average exercise price, Granted	9.63
Weighted-average exercise price, Exercised	2.68
Weighted-average exercise price, Expired or Canceled	1.56
Weighted-average exercise price, Forfeited	2.54
Weighted-average exercise price, Ending balance	3.12	$ 2.45
Weighted-average exercise price, Exercisable	2.25
Weighted-average exercise price, Vested or expected to vest	$ 2.98
Weighted-average remaining contractual life (in years)	6 years 9 months 26 days	7 years 4 months 10 days
Weighted-average remaining contractual life (in years), Exercisable	6 years 11 days
Weighted-average remaining contractual life (in years), Vested or expected to vest	6 years 9 months 18 days

Stockholders' Equity (Deficit) (Fair Value of Option Vested and Share-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Fair value of option vested and allocated share-based compensation expense	$ 264	$ 594	$ 925	$ 1,133
Research and Development Expense [Member] \| Employee [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Fair value of option vested and allocated share-based compensation expense	109	68	422	234
Research and Development Expense [Member] \| Non-Employee [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Fair value of option vested and allocated share-based compensation expense	7	28	28	59
General and Administrative Expense [Member] \| Employee [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Fair value of option vested and allocated share-based compensation expense	100	459	350	781
General and Administrative Expense [Member] \| Non-Employee [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Fair value of option vested and allocated share-based compensation expense	$ 48	$ 39	$ 125	$ 59

Stockholders' Equity (Deficit) (Summary of Activity Related to Restricted Stock Units) (Details)	9 Months Ended
	Sep. 30, 2013 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Balance, December 31, 2012	43,199
Balance, September 30, 2013	102,547
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Balance, December 31, 2012	43,199
Granted	59,348
Balance, September 30, 2013	102,547

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2013	Sep. 30, 2013
Unrecognized tax benefits		$ 0.0
Scenario, Forecast [Member]
Estimated annual effective tax rate	0.00%

Significant Agreements (Details) $ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
Significant Agreements (Details) $ in Thousands	Jul. 31, 2012 USD ($)	Feb. 28, 2011 USD ($) item	May 31, 2002 USD ($) shares	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2013 USD ($) shares	Sep. 30, 2012 USD ($)	Dec. 31, 2012 USD ($)
Long-term Purchase Commitment [Line Items]
Number of options outstanding, Granted \| shares						241,313
Contract revenue				$ 912	$ 3,411	$ 3,491	$ 12,694
Length of first option segment period						12 months
CMX001 [Member]
Long-term Purchase Commitment [Line Items]
Sublicense fee payable, maximum percentage						5.00%
CMX157 [Member]
Long-term Purchase Commitment [Line Items]
Sublicense fee payable, maximum percentage						10.00%
Merck, Sharp and Dohme Corp. [Member]
Long-term Purchase Commitment [Line Items]
Upfront payment, receivable	$ 17,500
Product royalty period	10 years
Regents Of University Of California [Member]
Long-term Purchase Commitment [Line Items]
Milestone payments			$ 3,400
Number of options outstanding, Granted \| shares			64,788
Sublicense fee percentage			50.00%
Royalties percentage			50.00%
Other expenses								$ 900
Research and Development Arrangement [Member]
Long-term Purchase Commitment [Line Items]
Contract revenue		$ 5,300
Number of extension periods \| item		4
Other segments, period		1 year
Maximum [Member] \| Merck, Sharp and Dohme Corp. [Member]
Long-term Purchase Commitment [Line Items]
Milestone payments	$ 151,000
Maximum [Member] \| Research and Development Arrangement [Member]
Long-term Purchase Commitment [Line Items]
Reimbursement revenue		$ 75,800
Maximum [Member] \| Research and Development Arrangement [Member] \| Scenario, Plan [Member]
Long-term Purchase Commitment [Line Items]
Contract revenue						$ 5,000